A front-runner coronavirus vaccine developed by drug giant Pfizer and German biotechnology firm BioNTech has shown 90% efficiency in the interim results of the third phase of clinical trials. This was reported by the press service of Pfizer.
Their vaccine has been tested on 43,500 people in six countries and no safety concerns have been raised.
The companies plan to apply for emergency approval to use the vaccine by the end of the month.
No vaccine has gone from the drawing board to being proven highly effective in such a short period of time.
Donald Trump, who had called Pfizer chief executive Albert Bourla to ask about the vaccine and previously accused regulators of a "political hit job" for slowing down a vaccine, celebrated the news.
STOCK MARKET UP
BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT
STOCK MARKET UP BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT NEWS!— Donald J. Trump (@realDonaldTrump) November 9, 2020
As we reported earlier, head of the Health Ministry Maksym Stepanov stated about the possibility of accession of Ukraine to the development of the vaccine held by British Company AstraZeneca.
“The Health Ministry is in constant connection with AstraZeneca Company that along with Oxford University develops the vaccine against the coronavirus; its production might be started soon. We also consider the possibility to include the Ukrainian capacities into the production of this vaccine,” Stepanov said.